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Abstract  
Antiphospholipid syndrome is an autoimmune disorder defined as association of vascular 
thrombosis and/or pregnancy complications with presence of antiphospholipid antibodies (lupus 
anticoagulant, anticardiolipin and anti-β2 glycoprotein I). It is the most common cause of acquired 
thrombophilia, and can occur as an independent entity or in relation with other diseases, especially 
systemic lupus erythematosus. Presence of antiphospholipid syndrome in systemic lupus 
erythematosus is additional vaso occlusive factor in already present inflammation, bringing further 
risk for thrombotic events. Clinical and serological manifestations of antiphospholipid syndrome and 
systemic lupus erythematosus are very similar, so possible connection for these two autoimmune 
disorders is assumed. 
 
 
 
 
 
 
 
 
 
Introduction 
Antiphospholipid syndrome (APS) is an 
autoimmune disorder defined as association of 
vascular thrombosis and/or pregnancy complications 
with presence of antiphospholipid antibodies (lupus 
anticoagulant, anticardiolipin and anti-β2 glycoprotein 
I). According to revised criteria, at least one clinical 
and one laboratory criteria are necessary for 
diagnosis (Table 1) [1].
 
The spectrum of clinical 
manifestations of APS is broad, because thrombosis 
can occur in both arterial and venous system and in 
the blood vessels of all sizes. Confirmation of 
antiphospholipid antibodies is very important step for 
diagnosis, but because they are polyclonal and 
heterogeneous, it is difficult to make a standardized 
test which includes them all. 
Antiphospholipid syndrome can occur as an 
independent entity and then is called primary. 
Secondary APS is most commonly seen in 
autoimmune diseases, but also in malignancies, 
hematological, infectious and neurological diseases. A 
special form is catastrophic APS, characterized by 
acute multiorgan failure caused by rapid 
microthrombosis [2]. 
Systemic lupus erythematosus (SLE) is an 
autoimmune disease characterized by autoantibodies 
formation and organ changes caused by inflammation 
and other blood vessel disorders. Beside familiar risk 
factors for thrombosis in patients with SLE, 
antiphospholipid antibodies are among most 
significant. Since positive lupus anticoagulant (LA) 
and/or anticardiolipin (aCL) antibodies are one of 
classificaton criteria for SLE, patients are regularly 
tested for their presence and their confirmation is 
additional risk factor for thrombosis [1, 3, 4]. 
Patients with primary APS can have clinical 
and serological manifestations as in SLE, but not 
fulfilling criteria for diagnosis of SLE [5,6]. Some of 
them over the years can develop SLE. Secondary 
APS is most commonly associated with SLE. These 
findings may suggest that there is possible overlaping 
between these two disorders.  
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Table 1: Classification criteria for Antiphosholipid syndrome. 
___________________________________________ 
Clinical criteria  
 
1. Vascular thrombosis  
One or more clinical episodes of arterial, venous, or small vessel 
thrombosis, in any tissue or organ. Thrombosis must be confirmed 
by objective validated criteria  
 
2. Pregnancy morbidity  
a. One or more unexplained deaths of a morphologically normal 
fetus at or beyond the 10th week of gestation, with normal fetal 
morphology documented by ultrasound or by direct examination of 
the fetus, or  
b. One or more premature births of a morphologically normal 
neonate before the 34th week of gestation because of: (i) eclampsia 
or severe preeclampsia defined according to standard definitions, or 
(ii) recognized features of placental insufficiency, or  
c. Three or more unexplained consecutive spontaneous abortions 
before the 10th week of gestation, with maternal anatomic or 
hormonal abnormalities and paternal and maternal chromosomal 
causes excluded.  
 
Laboratory criteria  
 
1. Lupus anticoagulant (LA) present in plasma, on two or more 
occasions at least 12 weeks apart, detected according to the 
guidelines of the International Society on Thrombosis and 
Haemostasis  
 
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum 
or plasma, present in medium or high titer (i.e. >40 GPL or MPL, or 
>the 99th percentile), on two or more occasions, at least 12 weeks 
apart, measured by a standardized ELISA (Enzyme-linked 
immunosorbent assay) 
 
3. Anti-β2 glycoprotein I antibody of IgG and/or IgM isotype in 
serum or plasma (in titer >the 99th percentile), present on two or 
more occasions, at least 12 weeks apart, measured by a 
standardized ELISA, according to recommended procedures 
___________________________________________ 
 
Pathogenesis of antiphospholipid 
syndrome 
Pathogenesis of APS is complex. 
Antiphospholipid antibodies are very heterogeneous, 
and though their name implies, they are not directed 
against phospholipids as such, but against 
phospholipid-binding proteins. The main autoantigen 
for antiphosholipid antibodies is β-2 glycoprotein I, 
plasma protein composed of five domains. Upon 
binding to an anionic phosholipid surface through 
domain V, the cryptic epitope on the domain I 
becomes exposed, alowing antiboides to bind [7-9].  
This antigene-antibody complex interact with  
receptors of different cells (endothelial, thrombocytes, 
monocytes) and activate them, causing increased 
tissue factor expression, cytokine and adhesion 
molecule release, therefore achieving prothrombotic 
potential [9-11]. 
Although APS is considered to be non 
inflammatory disorder, researches on animal models 
have found that complement activation and 
inflammation rather than thrombosis are essential in 
fetal loss [12]. The role of  β-glycoprotein I as a 
regulator protein of the complement system has been 
postulated,  so the presence of antiphosholipid 
antibodies may inhibit this function, leading to 
complement activation and consequential neutrophil 
attraction, activation of  neutrophils and monocytes  
and  the release of inflammatory mediators  [11, 14]. 
These findings are connected with the pathogenesis 
of SLE and can have therapeutic implication, such as 
therapy with humanized monoclonal antibody against 
complement protein C5 [13]. 
Patients with APS have occasional, mostly 
localized thrombotic events and rarely present with 
disseminated thrombosis despite continuously present 
antiphospholid antibodies. Since anion phospholipids 
are usually not exposed to circulation, it is assumed 
that occurrence of thrombosis requires "two hits". First 
hit is presence of antiphospholipid antibodies with 
procoagulant and proinflammatory potential and 
second one is stimulation of vascular structures and 
cells with cytokines, injury or local apoptosis, exposing 
anion phospholipids to antiphospholipid antibodies [8]. 
In the context of SLE, already present injury of the 
vascular structures and inflammation may enhance 
the thrombotic potential of antiphospholipid antibodies 
leading to thrombosis. 
 
Prevalence of antiphospholipid syndrome 
in systemic lupus erythematosus 
Prevalence of APS in SLE is 20-50%, and 
antiphospholipid antibodies occur in 5-70% of  SLE 
patients [15,16].
 
Large European cohort study of 1000 
APS patients from 13 countries demonstrated that 
primary APS was present in 53.1% of patients, and 
APS was associated with SLE in 36.2%, 80% of which 
had aCL antibodies, 20% had LA, and about 60% had 
both [17].
  
Prevalence of anti- β2 glycoprotein I  (GPI) 
antibodies in patients with SLE without thrombosis is 
7.8-34.9%, and in those with SLE and secondary APS  
is 35% [18]. Thrombosis is more frequent in patients 
with SLE and antiphospholipid antibodies compared to 
those with some other autoimmune disease and these 
antibodies [19]. Thrombosis in SLE is also associated 
with anti-β2 GPI antibodies of IgA isotype, which are 
not included in criteria for diagnosis of APS [20, 21]. 
Determination of these antibodies is recommended in 
case of clinical symptoms of SLE and/or APS, 
particularly if other tests for antiphospholipid 
antibodies are negative [22]. 
 
Clinical manifestations 
Among diverse clinical and laboratory 
manifestations of APS there are also those not 
included in classification criteria: heart valve changes, 
livedo reticularis, skin ulcerations, thrombocytopenia, 
nephropathy, cognitive dysfunction, migraine, 
epilepsy, aCL antibodies of IgA isotype, anti- β2 GPI 
antibodies of IgA isotype, anti-phosphatidylserin (aPS) 
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antibodies, anti-phosphatidiletanolamin (aPE)  
antibodies, anti-thrombin antibodies (aPT), antibodies 
to complex phosphatidylserin-prothrombin (aPS/PT), 
anti-anexin 5 antibodies [23-28]. Including these 
manifestations in classification criteria would decrease 
diagnostic specificity for APS, but the question 
remains when they should be considered in diagnosis 
establishment [1].   
As well as in patients with primary APS, 
clinical manifestations are diverse in patients with SLE 
and secondary APS with most common being lower 
extremities deep venus thrombosis (DVT), 
cerebrovascular insult and transitory ischemic attack, 
but some less frequent also occur, like myocardial 
infarction, avascular bone necrosis and spleen 
infarction [17, 29]. Interesting topic regards 
thrombocytopenia and APS nephropathy as non 
classification manifestations of APS  in patients with 
SEL.  
Thrombocytopenia is common in patients with 
SLE and secondary APS and more common than in 
those with primary APS [1, 30]. It is mostly mild with 
manifestations varying from bleeding to thrombosis. It 
is questionable when to regard thrombocytopenia in 
the presence of antiphopholipid antibodies as clinical 
non classification criteria for secondary APS and 
when as a diagnostic criteria for SLE. This is 
important issue, because it has therapeutic 
implications. 
Antiphosholipid syndrome nephropathy 
clinically manifests with arterial hypertension, low 
grade proteinuria and acute or chronic kidney failure. 
Study of Tektonidou et al. demonstrated that APS 
nephropathy occurs in 39.5% of patients with SLE and 
antiphospholipid antibodies, and in only 4.3% of those 
with SLE without antiphospholipid antibodies [31]. 
Nephropathy was confirmed by pathohistological 
analysis of kidney biopsies and was statistically 
strongly correlated to positive LA, aCL antibodies, 
livedo reticularis and arterial thrombosis. The authors 
concluded that APS nephropathy in patients with SLE 
represents an independent risk factor for arterial 
hypertension and serum creatinine levels, influencing 
poorer prognosis of kidney function. These results are 
significant for demonstration that pathohistological 
analysis of kidney biopsy is required for differentiation 
of patients with APS nephropathy from those with 
lupus nephritis. Pathology report affects treatment 
strategy, namely application of intensive 
immunosuppressive therapy. On the other hand, 
patients with SLE can have both lupus nephritis and 
APS nephropathy, which leads to worse prognosis of 
kidney function.  
 
Thromobosis risk in patients with 
systemic lupus erythematosus  
Longitudinal studies have confirmed that APS 
can develop in 50-70% of patients with SLE and 
antiphospholipid antibodies during 20 years of follow 
up [19]. Since patients with SLE can have 
antiphospholipid antibodies, it would be important to 
identify clinical and laboratory parameters predictive 
of future thrombosis. 
According to study results of Tarr et al. who 
followed 272 patients with SLE over 5 years, LA was 
most frequently associated with thrombotic events, 
namely neurological manifestations and lower 
extremities DVT [32]. Patients with long standing 
positivity of different antiphospholipid antibodies had 
the highest risk for thrombosis. A half of patients with 
SLE with antiphospholipid antibodies had thrombotic 
complications. When it comes to clinical 
manifestations of SLE,  lupus nephritis and Raynaud 
phenomenon are verified as risk factors for thrombotic 
events in patients with antiphospholipid antibodies 
[33]. 
In a study that retrospectively analyzed profile 
of 6 different antiphospholipid antibodies (LA, anti- β2 
GPI, aCL, aPE, aPT, aPS/PT) in 230 patients with 
SLE, a combination of LA, anti- β2 GPI and aPS/PT 
antibodies had the highest specificity for APS and was 
associated with higher risk for thrombosis and 
pregnancy complications compared to triple positivity 
of LA, anti- β2 GPI and aCL antibodies [34]. 
A recent cross sectional study of 211 patients 
with SLE analyzed independent thrombotic risk 
factors, conventional cardiovascular risk factors, 
antiphospholipid antibodies profile including non 
classification antiphospholipid antibodies and a profile 
of other antibodies. Arterial hypertension, 
hyperlipidemia, aCL, LA, anti-β2 GPI and aPS/PT 
antibodies were designated as independent risk 
factors for thrombosis and fetal loss during pregnancy 
[35]. 
 
Primary antiphospholipid syndrome and 
systemic lupus erythematosus 
It is a well known paradigm that patients with 
certain autoimmune disorder should be regularly 
evaluated for development of other autoimmune 
disease. Patients with SLE are followed for potential 
development of secondary APS. Still, there are few 
available studies that dealt with opposite question - 
whether patients with primary APS can develop SLE 
as well.  
Study analyzing 128 patients with primary 
APS demonstrated that 8.2% of them also developed 
SLE during 8 years of follow up [36]. Authors verified 
increased risk for SLE in patients with positive family 
history for SLE, Raynaud phenomenon, migraine, 
psychiatric disorders, haemolytic anemia, low C3 and 
C4 levels and positive Coombs test. Only positive 
Coombs test reached statistical significance as a risk 
factor for SLE and was designated as a potential 
Plavsic et al. Systemic Lupus Erythematosus and Antiphospholipid Syndrome 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Sep 15; 2(3):544-549.                                                                                                                                                                         547 
 
marker for SLE development. Retrospective study of 
Tarr et al. which analyzed 362 patients with SLE, 
demonstrated that primary APS was previously 
present in 7.2% of patients, and that patients with 
primary APS develop SLE on average after 5.5 years. 
[37].
 
McClain et al. analyzed significance of 
appearance of positive aCL antibodies before SLE 
development, and confirmed that patients with positive 
aCL antibodies fulfilled SLE criteria approximately 
over 3 years. Clinical disease course in these patients 
was more difficult and  positive aCL antibodies were 
significantly correlated with kidney lesions, 
neurological complications, thrombocytopenia and 
thrombosis [38]. Hungarian authors, who 
retrospectively analyzed 165 patients with primary 
APS, found that 63% of them still had primary APS 
after 5 years, that 14.4% developed undetermined 
systemic connective tissue disease and that 23% 
developed specific autoimmune disease (most often 
SLE, 8% of patients) [39]. Authors didn’t verify any 
possible laboratory prognostic marker for 
development of some of the systemic connective 
tissue diseases during transitional period from primary 
APS to definitive diagnosis of other autoimmune 
disease. 
Based on these findings, it can be concluded 
that patients with primary APS should be regularly 
followed for development of SLE. Some authors 
believe that primary APS is just an early phase in a 
dynamic process of transition to a defined 
autoimmune systemic disease [32,37]. 
 
Therapy 
Main therapeutic goal in patients with APS is 
a prevention of new thrombosis. There are no official 
guidelines and recommendations are mostly based on 
systematic reviews of published results of mainly 
observational studies. Clinical difference exists 
between patients with positive antiphospholipid 
antibodies without manifested APS and those with 
established APS. Treatment of APS in pregnancy is a 
separate issue. Therapeutic approach varies 
depending on clinical situation, so primary and 
secondary thromboprophylaxis can be discussed. 
Most studies dealing with primary 
thromboprophylaxis examined acetylsalycilic acid. 
Prospective double blind placebo controlled study that 
compared use of Aspirin (81 mg daily) to placebo in 
asymptomatic patients with positive antiphospholipid 
antibodies, didn’t confirm prophylactic effect of Aspirin 
on development of thrombosis [40]. Still, 
thromboprophylactic effect of Aspirin was 
demonstrated in patients with SLE compared to those 
without therapy [41]. After systematic literature review 
Tuthill et al. recommend use of low dose Aspirin in 
patients with persistently positive antiphospholipid 
antibodies (especially LA), with addition of 
hydroxychloroquine if SLE is also present [42]. 
Authors advise mandatory estimation of other 
thrombotic risk factors, their active reduction and 
treatment. In situations of increased risk for 
thrombosis, prophylactic use of low molecular weight 
heparin is advised. Antimalarics have anti-
inflammatory, immunomodulatory and metabolic 
effects, so hydroxychloroquine is recommended for all 
patients with SLE and positive antiphospholipid 
antibodies [43, 44].  
Patients with APS are at increased risk for 
recurrent thrombosis which makes issue of secondary 
prophylaxis very important. Therapeutic approach is 
based on anticoagulant therapy, but treatment goals 
are different depending on whether arterial or venous 
thrombosis happened. Based on recommendations 
from different authors, therapy of patients with APS 
and first episode of venous thrombosis consists of 
long term use of oral anticoagulants , with therapeutic 
range of INR (international normalized ratio) of 2-3 
[42, 45, 46]. Differences exist in recommendations for 
optimal INR therapeutic range in patients with first 
episode of arterial thrombosis or recurrent thrombosis. 
Some authors advise only oral anticoagulants  with 
INR range of 3-4, while others recommend INR range 
of 2-3, or use of oral anticoagulants (INR 2-3) and 
antiaggregation therapy [46, 47]. Large prospective 
studies are required for unified recommendation. 
Meanwhile therapy should be individualized, with 
respect to all potential thrombotic risk factors, but also 
potential bleeding risk factors. Modern therapeutic 
modalities have been debated during last 14th 
International Congress on Antiphospholipid 
Antibodies, namely direct oral thrombin inhibitors, 
inhibitors of factor Xa, statins, B cell inhibitors, 
inhibitors of complement components and peptide 
therapy [44].   
 
Is antiphospholipid syndrome a systemic 
autoimmune disorder? 
Patients with primary APS and those with SLE 
(without APS) have similarities that are serological 
(LA, aCL) and clinical (livedo reticularis, neurological 
and nephrological manifestations, thrombocytopenia) 
[48]. Many patients with primary APS have serological 
markers of SLE (antinuclear, anti ds-DNA, anti-
nucleosomal antibodies), and then they are said to 
have a “lupus like disease”. Some of them can 
develop SLE over years. On the other hand, 
prevalence of secondary APS is highest in patients 
with SLE, so it can be assumed that SLE represents 
an inflammatory basis for APS. Additionally, 
experimental models suggest significant role of 
complement system and inflammation in APS 
pathogenesis, which is similar to SLE pathogenesis 
[49-51]. New data indicate role of vitamin D in SLE 
pathogenesis and also very current are researches of 
vitamin D role in APS [52]. Based on many similarities 
with SLE, some authors indicate possible systemic 
character of APS and raise an intriguing question: are 
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APS and SLE two separate autoimmune disorders or 
represent one same autoimmune phenomenon? [53, 
54]. 
 
Conclusion 
Antiphospholipid syndrome is autoimmune 
disorder with complex pathophysiological 
mechanisms, diverse clinical and laboratory 
manifestations and insufficiently defined therapy 
recommendations. Knowing that certain 
manifestations are not included in classification 
criteria, it is clear that official criteria simply don’t apply 
to some patients. Still, it is questionable which 
situations require strict following of classification 
criteria and which don’t. That is why patients should 
be regarded individually, with respect to all thrombotic 
risk factors, clinical picture and availability of tests for 
antiphospholipid antibodies, but also to risks of 
possible complications of antithrombotic therapy.  
 
 
Figure 1: Possible clinical forms in evolution of SLE and APS. (SLE-  
systemic lupus erythematosus, APS- antiphospholipid syndrome). 
 
Patients with SLE can develop APS during 
disease course. Among all autoimmune diseases, 
secondary APS is most commonly seen in patients 
with SLE. On the other hand, patients with SLE can 
have antiphospholipid antibodies, but without clinical 
manifestations of APS. Also, patients with APS can 
develop SLE over years. All these clinical scenarios 
indicate that patients with SLE should be carefully 
observed for development of APS, but also vice versa, 
patients with APS should be monitored for 
development of other autoimmune disease, especially 
SLE (Figure 1).  
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